Management & Regulatory

Lonza Expands ADC Production with New Bioconjugation Suite in Switzerland
Management & Regulatory Lonza Expands ADC Production with New Bioconjugation Suite in Switzerland

Lonza has bolstered its presence in the field of antibody-drug conjugates (ADC) by extending its manufacturing collaboration with a renowned biopharma company. This strategic move involves the expansion of its bioconjugation operations at the Ibex Biopark located in Visp, Switzerland. Under this

Benitec Biopharma's Stock Soars Amidst Growing Cash Burn Concerns
Management & Regulatory Benitec Biopharma's Stock Soars Amidst Growing Cash Burn Concerns

Benitec Biopharma (NASDAQ:BNTC) has recently captured the attention of investors with a monumental surge in its stock price, boasting a remarkable 205% increase over the past year. This surge is particularly striking given that Benitec, a biotechnology firm focusing on gene therapy, has yet to

How Will Rentschler Biopharma's New Facility Impact Biotech Future?
Management & Regulatory How Will Rentschler Biopharma's New Facility Impact Biotech Future?

Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals and advanced therapy medicinal products (ATMPs), has taken a monumental step towards bolstering its operational capabilities. The German-based company has announced its

Eurofins Alphora Opens New High-Capacity API Manufacturing Facility
Management & Regulatory Eurofins Alphora Opens New High-Capacity API Manufacturing Facility

Eurofins CDMO Alphora Inc., a contract development and manufacturing organization (CDMO), has recently taken a significant leap in its operational capabilities. The company has unveiled a new Active Pharmaceutical Ingredient (API) manufacturing facility in Mississauga, Canada. This expansion

Roche Ends UCB Partnership on Anti-Tau Alzheimer's Drug Bepranemab
Management & Regulatory Roche Ends UCB Partnership on Anti-Tau Alzheimer's Drug Bepranemab

Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a d

How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?
Management & Regulatory How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?

Additive manufacturing, commonly known as 3D printing, has emerged as a revolutionary technology within the biopharmaceutical industry, offering considerable benefits. One of the most compelling advantages of additive manufacturing is its potential to optimize cleanroom space through the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later